Literature DB >> 11404425

Galpha(olf) levels are regulated by receptor usage and control dopamine and adenosine action in the striatum.

D Hervé1, C Le Moine, J C Corvol, L Belluscio, C Ledent, A A Fienberg, M Jaber, J M Studler, J A Girault.   

Abstract

In the striatum, dopamine D(1) and adenosine A(2A) receptors stimulate the production of cAMP, which is involved in neuromodulation and long-lasting changes in gene expression and synaptic function. Positive coupling of receptors to adenylyl cyclase can be mediated through the ubiquitous GTP-binding protein Galpha(S) subunit or through the olfactory isoform, Galpha(olf), which predominates in the striatum. In this study, using double in situ hybridization, we show that virtually all striatal efferent neurons, identified by the expression of preproenkephalin A, substance P, or D(1) receptor mRNA, contained high amounts of Galpha(olf) mRNA and undetectable levels of Galpha(s) mRNA. In contrast, the large cholinergic interneurons contained both Galpha(olf) and Galpha(s) transcripts. To assess the functional relationship between dopamine or adenosine receptors and G-proteins, we examined G-protein levels in the striatum of D(1) and A(2A) receptor knock-out mice. A selective increase in Galpha(olf) protein was observed in these animals, without change in mRNA levels. Conversely, Galpha(olf) levels were decreased in animals lacking a functional dopamine transporter. These results indicate that Galpha(olf) protein levels are regulated through D(1) and A(2A) receptor usage. To determine the functional consequences of changes in Galpha(olf) levels, we used heterozygous Galpha(olf) knock-out mice, which possess half of the normal Galpha(olf) levels. In these animals, the locomotor effects of amphetamine and caffeine, two psychostimulant drugs that affect dopamine and adenosine signaling, respectively, were markedly reduced. Together, these results identify Galpha(olf) as a critical and regulated component of both dopamine and adenosine signaling.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11404425      PMCID: PMC6762749     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  65 in total

Review 1.  Distribution, biochemistry and function of striatal adenosine A2A receptors.

Authors:  P Svenningsson; C Le Moine; G Fisone; B B Fredholm
Journal:  Prog Neurobiol       Date:  1999-11       Impact factor: 11.685

Review 2.  Addiction, dopamine, and the molecular mechanisms of memory.

Authors:  J D Berke; S E Hyman
Journal:  Neuron       Date:  2000-03       Impact factor: 17.173

3.  Regional, cellular, and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain.

Authors:  C Bergson; L Mrzljak; J F Smiley; M Pappy; R Levenson; P S Goldman-Rakic
Journal:  J Neurosci       Date:  1995-12       Impact factor: 6.167

Review 4.  The nucleus accumbens as a complex of functionally distinct neuronal ensembles: an integration of behavioural, electrophysiological and anatomical data.

Authors:  C M Pennartz; H J Groenewegen; F H Lopes da Silva
Journal:  Prog Neurobiol       Date:  1994-04       Impact factor: 11.685

5.  Effects of intraaccumbens dopamine agonist SK&F38393 and antagonist SCH23390 on locomotor activities in rats.

Authors:  M E Meyer
Journal:  Pharmacol Biochem Behav       Date:  1993-08       Impact factor: 3.533

6.  Quantitative electrophoretic transfer of polypeptides from SDS polyacrylamide gels to nitrocellulose sheets: a method for their re-use in immunoautoradiographic detection of antigens.

Authors:  P F Erickson; L N Minier; R S Lasher
Journal:  J Immunol Methods       Date:  1982-06-11       Impact factor: 2.303

7.  Mice deficient in G(olf) are anosmic.

Authors:  L Belluscio; G H Gold; A Nemes; R Axel
Journal:  Neuron       Date:  1998-01       Impact factor: 17.173

8.  D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.

Authors:  C R Gerfen; T M Engber; L C Mahan; Z Susel; T N Chase; F J Monsma; D R Sibley
Journal:  Science       Date:  1990-12-07       Impact factor: 47.728

9.  G(olf) and Gs in rat basal ganglia: possible involvement of G(olf) in the coupling of dopamine D1 receptor with adenylyl cyclase.

Authors:  D Hervé; M Lévi-Strauss; I Marey-Semper; C Verney; J P Tassin; J Glowinski; J A Girault
Journal:  J Neurosci       Date:  1993-05       Impact factor: 6.167

10.  Phenotypical characterization of the rat striatal neurons expressing the D1 dopamine receptor gene.

Authors:  C Le Moine; E Normand; B Bloch
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

View more
  53 in total

1.  Endogenous dopamine (DA) competes with the binding of a radiolabeled D₃ receptor partial agonist in vivo: a positron emission tomography study.

Authors:  Robert H Mach; Zhude Tu; Jinbin Xu; Shihong Li; Lynne A Jones; Michelle Taylor; Robert R Luedtke; Colin P Derdeyn; Joel S Perlmutter; Mark A Mintun
Journal:  Synapse       Date:  2011-03-21       Impact factor: 2.562

2.  Role of aberrant striatal dopamine D1 receptor/cAMP/protein kinase A/DARPP32 signaling in the paradoxical calming effect of amphetamine.

Authors:  Francesco Napolitano; Alessandra Bonito-Oliva; Mauro Federici; Manolo Carta; Francesco Errico; Salvatore Magara; Giuseppina Martella; Robert Nisticò; Diego Centonze; Antonio Pisani; Howard H Gu; Nicola B Mercuri; Alessandro Usiello
Journal:  J Neurosci       Date:  2010-08-18       Impact factor: 6.167

Review 3.  Inherited isolated dystonia: clinical genetics and gene function.

Authors:  William Dauer
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

Review 4.  Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface.

Authors:  John L Waddington; Colm O'Tuathaigh; Gerard O'Sullivan; Katsunori Tomiyama; Noriaki Koshikawa; David T Croke
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

5.  Evaluation of neuronal phosphoproteins as effectors of caffeine and mediators of striatal adenosine A2A receptor signaling.

Authors:  Bogachan Sahin; Stacey Galdi; Joseph Hendrick; Robert W Greene; Gretchen L Snyder; James A Bibb
Journal:  Brain Res       Date:  2006-12-06       Impact factor: 3.252

6.  Haloperidol regulates the state of phosphorylation of ribosomal protein S6 via activation of PKA and phosphorylation of DARPP-32.

Authors:  Emmanuel Valjent; Jesus Bertran-Gonzalez; Heather Bowling; Sébastien Lopez; Emanuela Santini; Miriam Matamales; Alessandra Bonito-Oliva; Denis Hervé; Charles Hoeffer; Eric Klann; Jean-Antoine Girault; Gilberto Fisone
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

7.  Acute administration of dopaminergic drugs has differential effects on locomotion in larval zebrafish.

Authors:  T D Irons; P E Kelly; D L Hunter; R C Macphail; S Padilla
Journal:  Pharmacol Biochem Behav       Date:  2012-12-28       Impact factor: 3.533

8.  Comparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds.

Authors:  Robert R Luedtke; Yogesh Mishra; Qi Wang; Suzy A Griffin; Cathy Bell-Horner; Michelle Taylor; Suwanna Vangveravong; Glenn H Dillon; Ren-Qi Huang; David E Reichert; Robert H Mach
Journal:  ACS Chem Neurosci       Date:  2012-10-12       Impact factor: 4.418

Review 9.  Behavioral genetic contributions to the study of addiction-related amphetamine effects.

Authors:  Tamara J Phillips; Helen M Kamens; Jeanna M Wheeler
Journal:  Neurosci Biobehav Rev       Date:  2007-11-29       Impact factor: 8.989

10.  Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease.

Authors:  Jean-Christophe Corvol; Marie-Paule Muriel; Emmanuel Valjent; Jean Féger; Naïma Hanoun; Jean-Antoine Girault; Etienne C Hirsch; Denis Hervé
Journal:  J Neurosci       Date:  2004-08-04       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.